5–10x ARPU Through EHR Integration
OpenEvidence
The real prize is not more doctor searches, it is becoming software a hospital pays for because it saves work inside the chart. OpenEvidence starts with a low friction ad business, roughly $124 ARPU from pharma and device ads, then moves up to enterprise contracts once it sits inside Epic or Cerner workflows and helps with coding, prior auth, drug checks, notes, and orders. That shift makes pricing look more like clinical software than media.
-
The 5 to 10x step up is easiest to see against existing benchmarks. OpenEvidence has been monetizing free physician usage at about $124 ARPU, while UpToDate sells hospitals at roughly $500 per seat. That already implies about 4x higher value before deeper workflow tools like charting and coding are added.
-
EHR integration changes what is being bought. A doctor using a web app is consuming information. A doctor using an embedded tool is completing billable and compliance heavy tasks without leaving the chart. That is why Abridge can charge about $500 per month per clinician and scaled to 60,000 plus clinicians after Epic and Athenahealth integrations.
-
The broader TAM comes from consolidation. Hospitals today pay different vendors for reference, drug data, documentation, and prior auth. If OpenEvidence becomes the single layer that answers a question, drafts the note, suggests the code, and checks the medication in one place, budget comes from several software lines instead of one reference tool line.
From here, the winning products in clinical AI are likely to look less like standalone search tools and more like embedded operating layers inside the EHR. If OpenEvidence keeps extending from bedside answers into documentation and revenue cycle tasks, enterprise revenue should rise faster than physician growth, and the company will start competing for much larger hospital software budgets.